文档介绍：PO Box 2345, Beijing 100023, China World J Gastroenterol 2004;10(8):1146-1151
Fax: +86-10-85381893 World Journal of Gastroenterology
E-mail: wjg@ yright © 2004 by The WJG Press ISSN 1007-9327
• LIVER CANCER •
Autologous cytokine-induced killer cell therapy in clinical trial phase
I is safe in patients with primary hepatocellular carcinoma
Ming Shi, Bing Zhang, Zi-Rong Tang, Zhou-Yun Lei, Hui-Fen Wang, Yong-Yi Feng, Zhen-Ping Fan,
Dong-Ping Xu, Fu-Sheng Wang
Ming Shi, Bing Zhang, Zi-Rong Tang, Zhou-Yun Lei, Hui-Fen INTRODUCTION
Wang, Yong-Yi Feng, Zhen-Ping Fan, Dong-Ping Xu, Fu-Sheng
Wang, Division of Biological Engineering, Institute of Infectious Primary hepatocellular carcinoma (HCC) represents one of the
Diseases, 302 Hospital of PLA, Beijing 100039, China most lethal neoplasms worldwide with a particularly high
[1]
Correspondence to: Dr. Fu-Sheng Wang, Research Center of prevalence in China . Chronic viral hepatitis patients, especially
Biotherapy, Beijing Institute of Infectious Diseases, 302 Hospital of hepatitis B or C patients, often fall victims to liver cirrhosis and
PLA, Beijing 100039, China. ******@public..cn subsequent HCC[2,3]. The high percentage of chronicity may
Telephone: +86-10-66933332 Fax: +86-10-63831870 be due to the bative mechanisms of the virus. In
Received: 2003-08-23 Accepted: 2003-10-22 cirrhotic patients, the incidence of HCC